Lv1
66 积分 2025-01-11 加入
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
1个月前
已关闭
Nivolumab in Previously Untreated Melanoma withoutBRAFMutation
1个月前
已完结
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
1个月前
已完结
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
1个月前
已完结
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
1个月前
已完结
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
1个月前
已完结
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
1个月前
已完结
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
1个月前
已完结
Combination locoregional and systemic therapies in hepatocellular carcinoma
5个月前
已完结
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study
5个月前
已完结
皖公网安备34019202002308
